Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Effective as of December20, 2018, Mark Glickman, Chief Commercial Officer of the Company, was determined to be an “executive officer” of Esperion Therapeutics,Inc. (the “Company”) as such term is defined under Rule3b-7 under the Exchange Act, and an “officer” as such term is defined under Rule16a-1(f)of the Exchange Act.

In addition, effective as of December20, 2018, Narendra Lalwani Ph.D. ceased to be an “executive officer” of the Company as such term is defined under Rule3b-7 under the Exchange Act, and an “officer” as such term is defined under Rule16a-1(f)of the Exchange Act. Dr.Lalwani remains as an employee of the Company and shall continue to serve as the Company’s Executive Vice President, Research& Development.

About Esperion Therapeutics,Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.